Terms: = Kidney tumors AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
22 results:
1. Clinical Efficacy of Bushen Yiqi Fuzheng Decoction Combined with Sunitinib in the Treatment of Postoperative Patients with Renal Cell Carcinoma and Its Influence on Their Immune Function.
Zhang L; Liu L; Zhao L; Yuan X; Wang Y; Yang J
Arch Esp Urol; 2023 Sep; 76(7):538-547. PubMed ID: 37867340
[TBL] [Abstract] [Full Text] [Related]
2. timp1 shapes an immunosuppressive microenvironment by regulating anoikis to promote the progression of clear cell renal cell carcinoma.
Li Q; Wei K; Zhang X; Lv Y; Li M; Zhou C; Su S; Hou D; Hou J
Aging (Albany NY); 2023 Sep; 15(17):8908-8929. PubMed ID: 37688768
[TBL] [Abstract] [Full Text] [Related]
3. Identifying Prognostic Biomarkers Related to m6A Modification and Immune Infiltration in Renal Cell Carcinoma.
Ye J; Li P; Zhang H; Wu Q; Yang D
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360294
[TBL] [Abstract] [Full Text] [Related]
4. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract] [Full Text] [Related]
5. A seven-gene signature model predicts overall survival in kidney renal clear cell carcinoma.
Chen L; Xiang Z; Chen X; Zhu X; Peng X
Hereditas; 2020 Sep; 157(1):38. PubMed ID: 32883362
[TBL] [Abstract] [Full Text] [Related]
6. Identification of potential key genes and key pathways related to clear cell renal cell carcinoma through bioinformatics analysis.
Zhai W; Lu H; Dong S; Fang J; Yu Z
Acta Biochim Biophys Sin (Shanghai); 2020 Aug; 52(8):853-863. PubMed ID: 32556097
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with kidney Cancer.
Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
[TBL] [Abstract] [Full Text] [Related]
8. The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and prognosis Prediction Approaches in kidney Cancer.
Liang J; Liu Z; Zou Z; Tang Y; Zhou C; Yang J; Wei X; Lu Y
Sci Rep; 2018 Apr; 8(1):6570. PubMed ID: 29700419
[TBL] [Abstract] [Full Text] [Related]
9. Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma.
Beardo P; Truan Cacho D; Izquierdo L; Alcover-Garcia JB; Alcaraz A; Extramiana J; Mallofré C
Pathol Oncol Res; 2019 Jan; 25(1):289-299. PubMed ID: 29103203
[TBL] [Abstract] [Full Text] [Related]
10. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
[TBL] [Abstract] [Full Text] [Related]
11. KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin.
Fan S; Li X; Tie L; Pan Y; Li X
Oncotarget; 2016 Mar; 7(12):13520-37. PubMed ID: 26575329
[TBL] [Abstract] [Full Text] [Related]
12. Imbalance between MMP-2, 9 and timp-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways.
Lu H; Cao X; Zhang H; Sun G; Fan G; Chen L; Wang S
Tumour Biol; 2014 Oct; 35(10):9807-13. PubMed ID: 24986570
[TBL] [Abstract] [Full Text] [Related]
13. Tumor cell-derived timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
Schelter F; Grandl M; Seubert B; Schaten S; Hauser S; Gerg M; Boccaccio C; Comoglio P; Krüger A
Clin Exp Metastasis; 2011 Dec; 28(8):793-802. PubMed ID: 21789719
[TBL] [Abstract] [Full Text] [Related]
14. Expression of erythropoietin and its receptor in human renal cell carcinoma.
Papworth K; Bergh A; Grankvist K; Ljungberg B; Rasmuson T
Tumour Biol; 2009; 30(2):86-92. PubMed ID: 19407488
[TBL] [Abstract] [Full Text] [Related]
15. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract] [Full Text] [Related]
16. Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma.
Kawata N; Nagane Y; Igarashi T; Hirakata H; Ichinose T; Hachiya T; Takimoto Y; Takahashi S
Urology; 2006 Sep; 68(3):523-7. PubMed ID: 16979746
[TBL] [Abstract] [Full Text] [Related]
17. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
Fergelot P; Rioux-Leclercq N; Patard JJ
Prog Urol; 2005 Dec; 15(6):1021-9. PubMed ID: 16429647
[TBL] [Abstract] [Full Text] [Related]
18. [Polycythaemia and renal cancer. Report of 5 cases].
Dahan M; Peyromaure M; Debré B; Zerbib M
Prog Urol; 2004 Jun; 14(3):401-2. PubMed ID: 15373186
[TBL] [Abstract] [Full Text] [Related]
19. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients.
Battagli C; Uzzo RG; Dulaimi E; Ibanez de Caceres I; Krassenstein R; Al-Saleem T; Greenberg RE; Cairns P
Cancer Res; 2003 Dec; 63(24):8695-9. PubMed ID: 14695183
[TBL] [Abstract] [Full Text] [Related]
20. Erythropoietin in urologic oncology.
Albers P; Heicappell R; Schwaibold H; Wolff J;
Eur Urol; 2001 Jan; 39(1):1-8. PubMed ID: 11173931
[TBL] [Abstract] [Full Text] [Related]
[Next]
